HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH RSS TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Amirav, I. Articles by Groshar, D. Search for Related Content PubMed PubMed Citation Articles by Amirav, I. Articles by Groshar, D.

ß-Agonist Aerosol Distribution in Respiratory Syncytial Virus Bronchiolitis in Infants

¹ Department of Pediatric Pulmonology, Rebecca Sieff Governmental Hospital, Safed, Israel
² Department of Pediatrics, Rebecca Sieff Governmental Hospital, Safed, Israel
³ Department of Nuclear Medicine, Rebecca Sieff Governmental Hospital, Safed, Israel
⁴ Department of Nuclear Medicine, Bnai Zion Medical Center, Haifa, Israel
⁵ Barnett Medical Aerosol Research Laboratory, St. Joseph Hospital, McMaster University, Hamilton, Ontario, Canada
⁶ Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel

Bronchodilator aerosols are frequently administered to infants with bronchiolitis but with little success. The efficacy of aerosol treatments depends mainly on adequate targeting of the aerosol particles to the inflamed airways. This study evaluated the lower respiratory tract distribution characteristics of nebulized bronchodilators in infants with acute bronchiolitis. Methods: Twelve infants (mean age ± SD, 8 mo ± 4 mo) who were admitted for acute respiratory syncytial virus bronchiolitis were treated with ^99mTc-albuterol aerosol. -Scintigraphy was used to assess total body and lung deposition as well as pulmonary distribution of the medication. Results: Of the total 6-min nebulized dose (i.e., drug aerosol dose leaving the nebulizer [not the nebulizer charge]), 1.5% ± 0.7% reached the right lung, with only approximately one third of that (0.6%) penetrating to the peripheral lung zone. There was 7.8% ± 4.9% deposition in the upper respiratory and gastrointestinal tracts and 10%–12% remained on the face. No correlation was found between any of the deposition indices and the clinical response data or any of the demographic parameters (e.g., height, weight, body surface area, or clinical score). Conclusion: Poor total aerosol deposition in infants may be related as much to their small conducting airways as to the disease state. There is considerable room for improvement in aerosol delivery in this age group, with greater emphasis on targeting narrowed peripheral airways with superfine aerosols.

Key Words: aerosol • bronchiolitis • infants • inhalation therapy

This article has been cited by other articles:

				G. Cambonie, C. Milesi, S. Fournier-Favre, F. Counil, S. Jaber, J.-C. Picaud, and S. Matecki Clinical Effects of Heliox Administration for Acute Bronchiolitis in Young Infants Chest, March 1, 2006; 129(3): 676 - 682. [Abstract] [Full Text] [PDF]

				I Amirav, I Balanov, M Gorenberg, D Groshar, and A S Luder Nebuliser hood compared to mask in wheezy infants: aerosol therapy without tears! Arch. Dis. Child., August 1, 2003; 88(8): 719 - 723. [Abstract] [Full Text] [PDF]